More U.S. Senators are urging the Food and Drug Administration to speed up regulations for CBD.
Sen. Richard Blumenthal (D-CT) said on Tuesday that he is urging the FDA to issue guidance so that CBD products can be lawfully marketed. Blumenthal and five of his colleagues also sent a letter to FDA expressing their desire to speed up the rule making process.
“What we need to do is stop the bad actors, rid the market of unsubstantiated and inaccurate health claims, make sure the good guys have a leveled playing field where truth and accuracy are valued and rewarded by consumers and by the regulatory framework,” he said.
“Hemp growers, manufacturers, food producers and most important, consumers, all deserve a regulatory framework that will set rules for classification, labeling, marketing, quality and other important features so that we stop the Wild West claims and make available products that are truly helpful and beneficial to consumers,” he added.
“The treatment of pain, anxiety, inflammation, other kinds of maladies may be aided by CBD and consumers deserve the benefits of those treatments but they also deserve to know the truth about the oils, lotions, gummies and other products that are out there.”
In a radio interview with WTIC, Blumental said, “Everybody’s interest is in the FDA doing its job and it has been lagging and laggard, and that’s why I’m demanding that in fact it do its job,” he said. “The FDA is chronically slow.”
“The FDA’s failure to finalize and implement a regulatory framework for CBD, including labeling, quality, marketing, and sale of CBD-containing products, is putting consumers at risk and inhibiting the industry,” Blumenthal also stated in a press release.